Phase B-STYPE
II I-STYPE
Trial I-STYPE
of O
Cediranib O
in O
Combination O
With O
Cisplatin O
and O
Pemetrexed O
in O
Chemotherapy O
- O
Naïve O
Patients O
With O
Unresectable O
Malignant O
Pleural O
Mesothelioma O
( O
SWOG O
S0905 O
) O
Phase B-STYPE
II I-STYPE
Trial I-STYPE
of O
Cediranib O
in O
Combination O
With O
Cisplatin O
and O
Pemetrexed O
in O
Chemotherapy O
- O
Naïve O
Patients O
With O
Unresectable O
Malignant O
Pleural O
Mesothelioma O
( O
SWOG O
S0905 O
) O
MDAnneSTsao B-AUTH

Phase B-STYPE
II I-STYPE
Trial I-STYPE
of O
Cediranib O
in O
Combination O
With O
Cisplatin O
and O
Pemetrexed O
in O
Chemotherapy O
- O
Naïve O
Patients O
With O
Unresectable O
Malignant O
Pleural O
Mesothelioma O
( O
SWOG O
S0905 O
) O
10.1200 O
/ O
JCO.19 O

Accepted O
on O
July O
9 O
, O
2019 O
and O
published O
at O
jco.org O
on O
August O
6 O
, O
2019 O
: O
MDAnneSTsao O
astsao@mdanderson.org O
. O
MDJielingMiao B-AUTH
MDIgnacioIWistuba B-AUTH
MDNicholasJVogelzang B-AUTH
MD O
, O
PhDJohnVHeymach B-AUTH
MDFrankVFossella B-AUTH
MDCharlesLu B-AUTH
MDMarioRVelasco B-AUTH
MDBrandyBox B-AUTH
- I-AUTH
Noriega I-AUTH
MDJamesGHueftle B-AUTH
MDShirishGadgeel B-AUTH
PhDMaryWRedman B-AUTH
MDDavidRGandara B-AUTH
MDKarenKelly B-AUTH
AmgenJohnson&Johnson O

Phase B-STYPE
II I-STYPE
Trial I-STYPE
of O
Cediranib O
in O
Combination O
With O
Cisplatin O
and O
Pemetrexed O
in O
Chemotherapy O
- O
Naïve O
Patients O
With O
Unresectable O
Malignant O
Pleural O
Mesothelioma O
( O
SWOG O
S0905 O
) O
MDAnneSTsao B-AUTH

astsao@mdanderson.org O
. O
MDAnneSTsao B-AUTH
MD O
Anne B-AUTH
S I-AUTH
Tsao I-AUTH
astsao@mdanderson.org O
. O
MDJielingMiao B-AUTH
MDJielingMiao B-AUTH
MD O
Jieling O
Miao O
MDIgnacioIWistuba B-AUTH
MDIgnacioIWistuba B-AUTH
MD O
Ignacio B-AUTH
I I-AUTH
Wistuba I-AUTH
MDNicholasJVogelzang B-AUTH
MDNicholasJVogelzang B-AUTH
MD O
Nicholas B-AUTH
J I-AUTH
Vogelzang I-AUTH
MD O
, O
PhDJohnVHeymach B-AUTH
MD O
, O
PhDJohnVHeymach B-AUTH
MD O
, O
PhD O
John B-AUTH
V I-AUTH
Heymach I-AUTH
MDFrankVFossella B-AUTH
MDFrankVFossella B-AUTH
MD O
Frank B-AUTH
V I-AUTH
Fossella I-AUTH
MDCharlesLu B-AUTH
MDCharlesLu B-AUTH
MD O
Charles B-AUTH
Lu I-AUTH
MDMarioRVelasco B-AUTH
MDMarioRVelasco B-AUTH
MD O
Mario B-AUTH
R I-AUTH
Velasco I-AUTH
MDBrandyBox B-AUTH
- I-AUTH
Noriega I-AUTH
MDBrandyBox B-AUTH
- I-AUTH
Noriega I-AUTH
MD O
Brandy B-AUTH
Box I-AUTH
- I-AUTH
Noriega I-AUTH
MDJamesGHueftle B-AUTH
MDJamesGHueftle B-AUTH
MD O
James B-AUTH
G I-AUTH
Hueftle I-AUTH
MDShirishGadgeel B-AUTH
MDShirishGadgeel B-AUTH
MD O
Shirish B-AUTH
Gadgeel I-AUTH
PhDMaryWRedman B-AUTH
PhDMaryWRedman B-AUTH
PhD O
Mary B-AUTH
W I-AUTH
Redman I-AUTH
MDDavidRGandara B-AUTH
MDDavidRGandara B-AUTH
MD O
David B-AUTH
R I-AUTH
Gandara I-AUTH
MDKarenKelly B-AUTH
MDKarenKelly B-AUTH
MD O
Karen B-AUTH
Kelly I-AUTH
AmgenJohnson&Johnson O
AmgenJohnson&Johnson O
Amgen O
Johnson O
& O
Johnson O
Pfizer O
, O
MerckBristol- O
MyersSquibb O
Pfizer O
, O
MerckBristol- O
MyersSquibb O
Pfizer O
, O
Merck O
Bristol- O
Myers O
Squibb O
EliLilly O
EliLilly O
Eli O
Lilly O
Celgene O
Celgene O
Celgene O
Astrazeneca O
Astrazeneca O
Astrazeneca O
EliGenentech O
EliGenentech O
Eli O
Genentech O
Lilly O
Lilly O
Lilly O
Honoraria O
: O
Merck O
Honoraria O
: O
Merck O
Honoraria O
: O
Merck O
AbbVie O
, O
Janssen O
, O
EMD O
Serono O
, O
Merck O
, O
PfizerAstrazenecaRegeneron O
AbbVie O
, O
Janssen O
, O
EMD O
Serono O
, O
Merck O
, O
PfizerAstrazenecaRegeneron O
AbbVie O
, O
Janssen O
, O
EMD O
Serono O
, O
Merck O
, O
Pfizer O
Astrazeneca O
Regeneron O
Genentech O
, O
Merck O
, O
RegeneronEliAstrazeneca O
Genentech O
, O
Merck O
, O
RegeneronEliAstrazeneca O
Genentech O
, O
Merck O
, O
Regeneron O
Eli O
Astrazeneca O
AbbVieEmdLilly O
AbbVieEmdLilly O
AbbVie O
Emd O
Lilly O
MerckSerono O
MerckSerono O
Merck O
Serono O
Department O
of O
Thoracic O
and O
Head O
and O
Neck O
Medical O
Oncology O

TX O
Department O
of O
Thoracic O
and O
Head O
and O
Neck O
Medical O
Oncology O
The O
University O
of O
Texas O
MD O
Anderson O
Cancer O
Center O
Unit O
432 O
, O
1515 O
Holcombe O
Blvd O
77030 O
Houston O

TX O
Unit O
432 O
, O
1515 O
Holcombe O
Blvd O
77030 O
Houston O
TX O
Guardant O
Health O
, O
CellMax O
Life O
, O
Pfizer O
Research O
Funding O
: O
Genentech O
( O
Inst O
) O
, O
AstraZeneca O
( O
Inst O
) O

MedImmune O
( O
Inst O
) O
Guardant O
Health O
, O
CellMax O
Life O
, O
Pfizer O
Research O
Funding O
: O
Genentech O
( O
Inst O
) O
, O
AstraZeneca O
( O
Inst O
) O
MedImmune O
( O
Inst O
) O
MedImmune O
( O
Inst O
) O
Phase B-STYPE
II I-STYPE
Trial I-STYPE
of O
Cediranib O
in O
Combination O
With O
Cisplatin O
and O
Pemetrexed O
in O
Chemotherapy O
- O
Naïve O
Patients O
With O
Unresectable O
Malignant O
Pleural O
Mesothelioma O
( O
SWOG O
S0905 O
) O
10.1200 O
/ O
JCO.19 O
Accepted O
on O
July O
9 O
, O
2019 O
and O
published O
at O
jco.org O
on O
August O
6 O
, O
2019 O
: O

Malignant O
pleural O
mesothelioma O
( O
MPM O
) O
is O
a O
rare O
disease O
with O
few O
treatment O
options O
and O
poor O
survival O
outcomes O
. O
1 O
Identifying O
targets O
for O
therapy O
is O
challenging O
. O
Mesothelioma O
secretes O
high O
levels O
of O
vascular O
endothelial O
growth O
factor O
( O
VEGF O
) O
and O
utilizes O
the O
platelet O
- O
derived O
growth O
factor O
and O
receptor O
( O
PDGF/ O
PDGFR O
) O
pathway O
for O
autocrine O
growth O
stimulation O
. O
[ O
2][3][4 O
] O
PDGFR O
inhibition O
increases O
chemotherapy O
uptake O
into O
tumor O
cells O
via O
pericyte O
manipulation O
and O
decreased O
interstitial O
fluid O
pressure O
. O
5,6 O
These O
factors O
suggest O
that O
the O
angiogenic O
pathway O
is O
clinically O
relevant O
and O
that O
targeting O
both O
VEGF O
and O
PDGF O
with O
systemic O
chemotherapy O
may O
be O
beneficial O
. O

In O
2003 O
, O
cisplatin O
- O
pemetrexed O
received O
regulatory O
approval O
for O
use O
in O
the O
front O
- O
line O
setting O
1 O
and O
, O
to O
date O
, O
remains O
a O
standard O
of O
care O
worldwide O
. O
However O
, O
in O
2016 O
, O
the O
phase O
II O
and O
III O
Mesothelioma O
Avastin O
Cisplatin O
Pemetrexed O
Study O
( O
MAPS O
; O
ClinicalTrials O
. O
gov O
identifier O
: O
NCT00651456 O
) O
7 O
demonstrated O
that O
bevacizumab O
combined O
with O
cisplatin O
- O
pemetrexed O
increased O
survival O
outcomes O
. O
7 O
In O
addition O
, O
in O
2017 O
, O
the O
phase O
II O
LUME O
- O
Meso O
trial O
( O
ClinicalTrials.gov O
identifier O
: O
NCT01907100 O
) O
demonstrated O
a O
progressionfree O
survival O
( O
PFS O
) O
benefit O
with O
the O
addition O
of O
nintedanib O
, O
a O
VEGF O
receptor O
( O
VEGFR O
) O
inhibitor O
, O
to O
cisplatin O
- O
pemetrexed O
. O
8 O
However O
, O
in O
September O
2018 O
, O
the O
subsequent O
phase O
III O
LUME O
- O
Meso O
trial O
was O
negative O
for O
a O
PFS O
benefit O
. O
9 O
Antiangiogenics O
have O
not O
received O
agency O
approval O
yet O
, O
but O
bevacizumab O
is O
commonly O
administered O
in O
addition O
to O
platinum O
- O
pemetrexed O
in O
the O
frontline O
setting O
. O

Cediranib O
( O
AstraZeneca O
, O
Cheshire O
, O
United O
Kingdom O
) O
, O
an O
oral O
tyrosine O
kinase O
inhibitor O
of O
VEGFR O
1,2,3 O
and O
PDGFR O
has O
been O
evaluated O
in O
mesothelioma O
as O
monotherapy O
and O
in O
combination O
with O
chemotherapy O
. O
Southwest O
Oncology O
Group O
trial O
SWOG O
0509 O
reported O
a O
9 O
% O
response O
rate O
and O
34 O
% O
disease O
stabilization O
with O
cediranib O
in O
patients O
with O
previously O
treated O
mesothelioma O
. O
10 O
We O
theorized O
that O
targeting O
VEGFR O
and O
PDGFR O
would O
enhance O
chemotherapy O
efficacy O
and O
potentially O
bypass O
resistance O
mechanisms O
of O
high O
VEGF O
ligand O
secretion O
. O
11 O
SWOG O
0905 O
was O
thus O
designed O
as O
a O
phase O
I O
and O
II O
front O
- O
line O
trial O
. O
The O
phase O
I O
trial O
established O
the O
maximum O
tolerated O
dose O
of O
cediranib O
at O
20 O
mg O
per O
day O
when O
combined O
with O
cisplatin O
- O
pemetrexed O
. O
12 O
Median O
RECIST O
v1.1 O
PFS O
was O
12.8 O
months O
, O
median O
modified O
RECIST O
( O
mRECIST O
) O
PFS O
was O
8.6 O
months O
, O
and O
median O
overall O
survival O
( O
OS O
) O
was O
16.2 O
months O
. O
12 O
Here O
, O
we O
report O
the O
results O
of O
the O
randomized B-STYPE
phase I-STYPE
II I-STYPE
SWOG I-STYPE
0905 I-STYPE
trial I-STYPE
. O

Key O
inclusion O
criteria O
included O
any O
histology O
MPM O
, O
measurable O
or O
nonmeasurable O
disease O
, O
Zubrod O
performance O
status O
( O
PS O
) O
equal O
or O
less O
than O
2 O
, O
and O
adequate O
organ O
function O
. O
Prior O
surgery O
or O
prior O
radiation O
therapy O
was O
allowed O
. O
No O
prior O
systemic O
therapy O
( O
chemotherapy O
or O
biologic O
) O
was O
allowed O
, O
unless O
it O
was O
neoadjuvant O
chemotherapy O
as O
part O
of O
definitive O
treatment O
( O
$ O
6 O
months O
before O
enrollment O
) O
. O
Patients O
were O
noted O
as O
having O
a O
prior O
surgery O
if O
the O
procedure O
was O
for O
definitive O
intent O
( O
ie O
, O
pleurectomy/ O
decortication O
or O
extrapleural O
pneumonectomy O
) O
. O
Exclusion O
criteria O
included O
severe O
systemic O
comorbid O
disease O
, O
significant O
cardiac O
history O
, O
uncontrolled O
hypertension O
, O
significant O
proteinuria O
, O
prolonged O
QTc O
interval O
, O
history O
of O
hemoptysis O
, O
bleeding O
diathesis O
, O
or O
an O
inability O
to O
take O
oral O
medication O
. O

The O
protocol O
and O
informed O
consent O
document O
were O
approved O
by O
the O
National O
Cancer O
Institute O
and O
the O
SWOG O
member O
sites O
' O
institutional O
review O
boards O
. O
This O
study O
was O
monitored O
by O
the O
SWOG O
Data O
and O
Safety O
Monitoring O
Committee O
. O

Radiographic O
imaging O
was O
performed O
after O
every O
two O
treatment O
cycles O
, O
and O
tumor O
measurements O
were O
determined O
by O
both O
RECIST O
v1.1 O
and O
mRECIST O
. O
13,14 O
mRECIST O
measurements O
rely O
on O
measuring O
tumor O
thickness O
perpendicular O
to O
the O
chest O
wall O
or O
mediastinum O
in O
two O
positions O
at O
three O
separate O
levels O
on O
computed O
tomography O
scans O
. O
These O
six O
measurements O
are O
summed O
into O
a O
pleural O
unidimensional O
measure O
. O
Any O
lymph O
nodes O
or O
bidimensionally O
measurable O
lesions O
are O
measured O
unidimensionally O
by O
RECIST O
. O
All O
measurements O
are O
added O
to O
obtain O
the O
total O
tumor O
measurement O
. O
Cisplatin B-DESC
( B-DOSAGE
75 I-DOSAGE
mg I-DOSAGE
/ I-DOSAGE
m I-DOSAGE
2 I-DOSAGE
) I-DOSAGE
plus O
pemetrexed  B-DESC
( B-DOSAGE
500 I-DOSAGE
mg I-DOSAGE
/ I-DOSAGE
m I-DOSAGE
2 I-DOSAGE
) I-DOSAGE
was O
administered O
intravenously O
every O
3  B-DOSAGE
weeks  I-DOSAGE
with  I-DOSAGE
dose  I-DOSAGE
modifications I-DOSAGE
conducted I-DOSAGE
by I-DOSAGE
standard I-DOSAGE
guidelines I-DOSAGE
. O
Carboplatin O
substitution O
was O
allowed O
if O
the O
patient O
developed O
toxicity O
to O
cisplatin O
. O
Cediranib B-DESC
20 B-DOSAGE
mg I-DOSAGE
per I-DOSAGE
day I-DOSAGE
or O
placebo B-DESC
was O
administered O
concomitantly  B-DOSAGE
on I-DOSAGE
day I-DOSAGE
1 I-DOSAGE
and I-DOSAGE
continued I-DOSAGE
daily I-DOSAGE
. O

Patients O
were O
randomly O
assigned O
with O
equal O
probability O
( O
1:1 O
) O
between O
cisplatin B-DESC
- B-DESC
pemetrexed I-DESC
with B-DESC
cediranib I-DESC
versus O
placebo B-DESC
. O
Randomization O
was O
stratified O
by O
PS O
( O
0 O
to O
1 O
v O
2 O
) O
and O
histology O
( O
epithelioid O
v O
biphasic O
or O
sarcomatoid O
) O
using O
a O
dynamic O
balancing O
algorithm O
. O
15 O
Patients O
were O
enrolled O
via O
a O
Web O
- O
based O
application O
and O
simultaneous O
randomization O
was O
performed O
by O
a O
computer O
program O
. O
Patients O
and O
investigators O
were O
blinded O
to O
the O
treatment O
arm O
. O

The O
primary O
objective O
was O
comparing O
PFS B-METRIC
by O
RECIST O
v1 O
. O
Time O
Since O
Registration O
( O
months O
) O
Progression−Free B-METRIC
Survival I-METRIC
( I-METRIC
% I-METRIC
) I-METRIC
Time I-METRIC
Since I-METRIC
Registration I-METRIC
( I-METRIC
months I-METRIC
) I-METRIC
Overall O
Survival O
( O
% O
) O
Time O
Since O
Registration O
( O
months O
) O
Progression−Free B-METRIC
Survival I-METRIC
( I-METRIC
% I-METRIC
) I-METRIC
and I-METRIC
OS I-METRIC
within I-METRIC
subgroups I-METRIC
defined I-METRIC
by I-METRIC
sex I-METRIC
, I-METRIC
prior I-METRIC
chemotherapy I-METRIC
, I-METRIC
prior I-METRIC
radiation I-METRIC
therapy I-METRIC
, I-METRIC
prior I-METRIC
surgery I-METRIC
, I-METRIC
performance I-METRIC
, I-METRIC
histology I-METRIC
, I-METRIC
and I-METRIC
age I-METRIC
were I-METRIC
performed I-METRIC
in I-METRIC
separate I-METRIC
models I-METRIC
, O
including O
a O
first O
order O
and O
interaction O
term O
between O
the O
subgroup O
and O
treatment O
using O
Cox O
proportional O
hazards O
regression O
model O
. O
Adjustments O
for O
multiple O
comparisons O
were O
not O
performed O
. O
A O
24-week O
landmark O
analysis O
postrandomization O
assessed O
the O
association O
between O
grade O
3 O
and O
4 O
hypertension O
or O
any O
grade O
3 O
and O
4 O
toxicity O
using O
Cox O
regression O
. O
HR O
and O
associated O
CIs O
were O
estimated O
using O
Cox O
proportional O
hazards O
regression O
model O
. O

Between O
October O
2011 O
and O
February O
2016 O
, O
97 O
patients O
were O
enrolled O
, O
of O
whom O
92 O
were O
found O
to O
be O
eligible O
. O
Reasons O
for O
ineligibility O
include O
two O
cases O
of O
inadequate O
renal O
function O
, O
one O
case O
of O
inadequate O
hematologic O
function O
, O
one O
case O
for O
which O
baseline O
scans O
were O
not O
performed O
within O
the O
protocol O
- O
specified O
timeframe O
, O
and O
one O
case O
where O
a O
second O
primary O
carcinoid O
tumor O
was O
found O
( O
Fig O
1 O
) O
. O
Among O
eligible O
patients O
, O
median O
age O
was O
72 O
years O
, O
with O
85 O
% O
of O
patients O
being O
men O
, O
75 O
% O
with O
epithelioid O
histology O
, O
and O
25 O
% O
with O
biphasic O
or O
sarcomatoid O
histology O
( O
Table O
1 O
) O
. O

Median O
follow O
- O
up O
time O
was O
31 O
months O
among O
patients O
who O
were O
still O
alive O
. O
Thirty O
- O
nine O
and O
41 O
deaths O
have O
been O
reported O
in O
the O
cediranib B-DESC
and O
placebo B-DESC
arms B-DESC
, O
respectively O
. O
Two O
measurement O
systems O
- O
RECIST O
v1.1 O
and O
mRECIST O
- O
were O
performed O
on O
eligible O
patients O
for O
radiographic O
assessments O
by O
investigators O
. O
At O
baseline O
, O
75 O
patients O
were O
measurable O
by O
RECIST O
v1.1 O
and O
66 O
by O
mRECIST O
. O

The O
trial O
met O
its O
primary O
objective O
with O
an O
improved O
RECIST  B-METRIC
PFS  I-METRIC
in O
the O
cediranib B-DESC
arm  I-DESC
compared O
with O
the O
placebo B-DESC
arm  B-DESC
( B-RESULTS
HR I-RESULTS
, I-RESULTS
0.71 I-RESULTS
; I-RESULTS
80 I-RESULTS
% I-RESULTS
CI I-RESULTS
, I-RESULTS
0.54 I-RESULTS
to I-RESULTS
0.95 I-RESULTS
; I-RESULTS
P I-RESULTS
= I-RESULTS
.062 I-RESULTS
; I-RESULTS
median B-METRIC
PFS I-METRIC
, O
7.2 B-RESULTS
months I-RESULTS
v O
5.6 B-RESULTS
months I-RESULTS
; O
Fig O
2A O
and O
Table O
2 O
) O
. O
By O
mRECIST O 
measurements O
, O
PFS B-METRIC
was O
also O
improved O
in O
the O
cediranib O
arm O
but O
was O
not O
statistically O
significant O
( B-RESULTS
HR I-RESULTS
, I-RESULTS
0.77 I-RESULTS
; I-RESULTS
80 I-RESULTS
% I-RESULTS
CI I-RESULTS
, I-RESULTS
0.59 I-RESULTS
to I-RESULTS
1.02 I-RESULTS
; I-RESULTS
P I-RESULTS
= I-RESULTS
.12 I-RESULTS
; I-RESULTS
median I-RESULTS
, I-RESULTS
6.9 I-RESULTS
months I-RESULTS
v I-RESULTS
5.6 I-RESULTS
months I-RESULTS
) I-RESULTS
. O
There O
was O
no O
significant O
difference O
in O
OS O
. O
Median O
OS O
was O
10 O
months O
compared O
with O
8.5 O
months O
in O
the O
placebo O
arm O
( O
HR O
, O
0.88 O
; O
80 O
% O
CI O
, O
0.65 O
to O
1.17 O
; O
P O
= O
.28 O
) O
. O

The O
cediranib B-DESC
arm I-DESC
had O
a O
statistically O
significantly O
higher O
mRECIST O
response O
rate O
compared O
with O
the O
placebo B-DESC
arm I-DESC
( O
50 O
% O
v O
20 O
% O
; O
P O
= O
.006 O
) O
. O
Duration O
of O
response O
numerically O
favored O
the O
cediranib B-DESC
arm I-DESC
( O
HR O
, O
0.77 O
; O
80 O
% O
CI O
, O
0.41 O
to O
1.45 O
; O
4.1 O
months O
v O
3.7 O
months O
; O
P O
= O
.30 O
) O
. O
By O
RECIST O
v1.1 O
, O
the O
cediranib B-DESC
arm I-DESC
numerically O
improved O
the O
response O
rate O
( O
26 O
% O
v O
15 O
% O
; O
P O
= O
.15 O
) O
and O
duration O
of O
response O
( O
HR O
, O
0.67 O
; O
80 O
% O
CI O
, O
0.31 O
to O
1.43 O
; O
6 O
months O
v O
1.7 O
months O
; O
P O
= O
.25 O
) O
over O
that O
of O
the O
placebo B-DESC
. O
Figure O
3 O
depicts O
the O
waterfall O
plots O
by O
RECIST O
v1.1 O
and O
mRECIST O
. O

The O
following O
subgroup O
analyses O
were O
exploratory O
. O
Figure O
4 O
describes O
the O
subgroup O
analysis O
by O
forest O
plot O
. O
Patients O
with O
epithelioid O
histology O
( O
n O
= O
69 O
) O
had O
better O
survival O
outcomes O
( O
There O
is O
evidence O
to O
suggest O
that O
prior O
chemotherapy O
- O
that O
is O
, O
neoadjuvant O
treatment O
before O
MPM O
recurrence O
- O
is O
a O
poor O
prognostic O
factor O
. O
There O
were O
six O
patients O
in O
each O
arm O
who O
received O
prior O
chemotherapy O
. O
Median O
OS O
was O
6.7 O
months O
in O
previously O
treated O
patients O
compared O
with O
10.4 O
months O
in O
those O
with O
no O
prior O
chemotherapy O
( O
HR O
, O
1.8 O
; O
80 O
% O
, O
1.18 O
to O
2.74 O
; O
P O
= O
.038 O
) O
. O
Patients O
with O
prior O
chemotherapy O
exposure O
had O
worse O
response O
rates O
by O
RECIST O
v1.1 O
. O
( O
0 O
% O
v O
23 O
% O
; O
P O
= O
.091 O
) O
and O
mRECIST O
( O
11 O
% O
v O
40 O
% O
; O
P O
= O
.089 O
) O
. O

Although O
the O
subgroup O
analysis O
has O
small O
numbers O
, O
these O
analyses O
suggest O
possible O
differential O
effects O
within O
subgroups O
to O
the O
chemotherapy O
- O
cediranib O
combination O
. O
In O
the O
RECIST B-METRIC
v1.1 I-METRIC
PFS I-METRIC
subgroup I-METRIC
analysis I-METRIC
( O
Fig O
2A O
) O
, O
male B-RESULTS
patients I-RESULTS
( I-RESULTS
HR I-RESULTS
, I-RESULTS
0.63 I-RESULTS
; I-RESULTS
P I-RESULTS
= I-RESULTS
.03 I-RESULTS
) I-RESULTS
, I-RESULTS
patients I-RESULTS
with I-RESULTS
prior I-RESULTS
radiation I-RESULTS
therapy I-RESULTS
( I-RESULTS
HR I-RESULTS
, I-RESULTS
0.32 I-RESULTS
; I-RESULTS
P I-RESULTS
= I-RESULTS
.03 I-RESULTS
) I-RESULTS
, I-RESULTS
any I-RESULTS
prior I-RESULTS
surgical I-RESULTS
procedure I-RESULTS
( I-RESULTS
HR I-RESULTS
, I-RESULTS
0.55 I-RESULTS
; I-RESULTS
P I-RESULTS
= I-RESULTS
.04 I-RESULTS
) I-RESULTS
, I-RESULTS
and I-RESULTS
age I-RESULTS
65 I-RESULTS
years I-RESULTS
or I-RESULTS
older I-RESULTS
( I-RESULTS
HR I-RESULTS
, I-RESULTS
0.5 I-RESULTS
; I-RESULTS
P I-RESULTS
, I-RESULTS
.01 I-RESULTS
) I-RESULTS
seemed I-RESULTS
to I-RESULTS
benefit I-RESULTS
from I-RESULTS
the I-RESULTS
addition I-RESULTS
of I-RESULTS
cediranib I-RESULTS
. O
The O
same O
subgroups O
seemed O
to O
benefit O
in O
the O
mRECIST B-METRIC
PFS I-METRIC
subgroup I-METRIC
analyses I-METRIC
( B-RESULTS
Fig I-RESULTS
2B I-RESULTS
) I-RESULTS
. O
It O
should O
be O
noted O
that O
the O
older O
patients O
( O
age O
$ O
65 O
years O
) O
had O
less O
prior O
chemotherapy O
as O
part O
of O
definitive O
treatment O
( O
9 O
% O
v O
25 O
% O
; O
P O
= O
.04 O
) O
. O
Likely O
because O
of O
small O
sample O
sizes O
and O
number O
of O
events O
, O
there O
were O
no O
clear O
subgroup O
associations O
for O
comparison O
of O
OS O
between O
arms O
( O
Fig O
2C O
) O
. O

Patients O
in O
the O
cediranib B-DESC
arm I-DESC
received O
fewer O
cycles O
of O
chemotherapy O
( O
median O
, O
four O
v O
six O
; O
P O
= O
.41 O
) O
and O
fewer O
days O
of O
cediranib O
/ O
placebo O
use O
( O
median O
, O
80 O
days O
v O
124 O
days O
; O
P O
= O
.31 O
; O
Appendix O
Table O
A1 O
, O
The O
addition B-DESC
of I-DESC
cediranib I-DESC
to I-DESC
chemotherapy I-DESC
led O
to O
a O
higher O
rate O
of O
treatment O
- O
related O
adverse O
events O
compared O
with O
placebo B-DESC
( O
100 O
% O
v O
91 O
% O
; O
P O
= O
.06 O
) O
. O
Toxicities O
( O
any O
grade O
; O
Table O
3 O
) O
that O
were O
higher O
in O
the O
cediranib B-DESC
arm I-DESC
were O
anorexia O
( O
21 O
% O
) O
, O
and O
myelosuppression O
( O
44 O
% O
v O
30 O
% O
) O
. O
There O
were O
two O
cases O
of O
sinus O
bradycardia O
and O
one O
of O
supraventricular O
tachycardia O
in O
the O
cediranib B-DESC
arm I-DESC
compared O
with O
none O
in O
the O
placebo B-DESC
arm I-DESC
. O
The O
cediranib B-DESC
arm I-DESC
was O
associated O
with O
69 O
% O
grade O
3 O
and O
4 O
toxicities O
compared O
with O
57 O
% O
in O
the O
placebo B-DESC
arm I-DESC
( O
P O
= O
.13 O
) O
. O
Four O
deaths O
occurred O
: O
two O
in O
the O
cediranib B-DESC
and O
one O
in O
the O
placebo B-DESC
arm I-DESC
from O
respiratory O
failure O
, O
and O
one O
sudden O
death O
in O
the O
placebo B-DESC
arm I-DESC
. O

Grade O
3 O
and O
4 O
hypertension O
was O
not O
associated O
with O
worse O
prognosis O
. O
This O
was O
evaluated O
using O
a O
landmark O
analysis O
that O
evaluated O
the O
incidence O
of O
grade O
3 O
and O
4 O
hypertension O
within O
the O
six O
cycles O
of O
treatment O
and O
survival O
among O
patients O
who O
were O
alive O
at O
week O
24 O
after O
random O
assignment O
. O
In O
this O
landmark O
analysis O
, O
there O
were O
34 O
patients O
and O
35 O
patients O
included O
from O
the O
cediranib B-DESC
and O
placebo B-DESC
arms  I-DESC
, O
respectively O
. O
We O
similarly O
evaluated O
the O
association O
between O
any O
grade O
3 O
and O
4 O
toxicity O
and O
prognosis O
and O
showed O
no O
association O
( O
P O
= O
.32 O
; O
HR O
, O
0.77 O
) O
. O
